Abstract
No public abstract is available from the verified source records.
Michael Baboudjian, Alessandro Uleri, Giuseppe Fallara, Alberto Martini, Guillaume Ploussard
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Perioperative apalutamide in high-risk localized prostate cancer
10.1056/nejmoa2603878 · 2026
Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer
10.1200/jco.2017.73.9987 · 2017
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
10.1016/s0140-6736(21)02437-5 · 2022
20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years
10.1056/nejmoa1701830 · 2017
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
10.1016/s0140-6736(20)30314-7 · 2020
Pelvic lymph node dissection in prostate cancer: update from a randomized clinical trial of limited versus extended dissection
10.1016/j.eururo.2024.10.006 · 2025
Improved outcomes with enzalutamide in biochemically recurrent prostate cancer
10.1056/nejmoa2303974 · 2023
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
10.1016/s1470-2045(19)30688-6 · 2019
No additional external references are available.